Flouxetine

PreclinicalSmall molecule

MMinia University

Flouxetine is one of 5 small molecule programs targeting Amblyopia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AmblyopiaActive, not recruiting

AmblyopiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Amblyopia

#DrugCompanyPhaseTrials

Aricept

Eisai

Approved

2 2

Lodosyn

LLaTonya J. Hickson

Approved

—3

Bendopa

MMerz North America, Inc.

Depacon

1 5

Flouxetine

MMinia University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Amblyopia1 trial

Possible Beneficial Effects Of Combined Fluoxetine And Occlusion Therapy In Improving And Maintaining Vision In Amblyopia Using Optical Coherence Tomography Angiography (OCTA) And Visual Evoked Potential (VEP). The Aim Of The Study Is To Evaluate Possible Beneficial Effects For Different Age Groups.

Recruiting·MMinia University·N/A·NCT07417046·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Flouxetine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Flouxetine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Flouxetine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Minia University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMinia University

Flouxetine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Amblyopia1 trial

References

Drug Info

Quick Facts

Related News